OBS Group completes its 6th acquisition in Pakistan. The products acquired belong to different therapeutic classes including anti-infectives + oncology.
International pharmaceutical news
OBS Group completes its 6th acquisition in Pakistan
The products acquired belong to different therapeutic classes including anti-infectives and oncology.
The Harel Group acted as advisor to OBS
(International distribution) OBS Group, through its subsidiary AGP Limited, listed on the Pakistan Stock Exchange, has completed the acquisition of a portfolio of 22 pharmaceutical products from Sandoz AG. These products were previously marketed in Pakistan under the Sandoz brand. The acquisition of this product portfolio from Sandoz is part of AGP’s commitment to its shareholders to create value through organic and inorganic growth.
AGP’s current presence in the anti-infectives segment will be further strengthened with the acquisition of several Sandoz products in the category. In addition, its oncology division was also strengthened with the addition of acquired oncology products. AGP also plans to introduce new drugs to complement its existing and recently acquired product portfolio from Sandoz.
The products acquired belong to different therapeutic classes including anti-infectives and oncology. Some of the well-established brands that have been acquired include Ternelin and Zatofen, with exclusive licenses granted for the use of Amoxi-Clav, Azomax, and Ospamox in Pakistan in the general drug category, and Paclitaxel and Gemcitabine in the drug segment. ‘oncology.
This transaction was completed for OBS by The Harel Group, a business development advisor in the biopharmaceutical, medical devices, diagnostics and OTC sectors. “The Harel group played an essential role in the closing of this transaction. The group has an excellent network in the global pharmaceutical industry and has delivered on all of its promises, ”said Mr. Tarek Khan, President of the OBS Group.
“We are very proud to contribute to the successful conclusion of the transaction between OBS and Sandoz,” said Jacob Harel, President of the Harel Group. Harel continues: “Both companies are well recognized in the pharmaceutical industry, locally and globally. , and the merger of the two companies will benefit patients and support the business vision of both companies in Pakistan. “
About the OBS group
The OBS group was formed following the acquisition of Organon Pakistan by Mr. Tarek Khan in 2006. The group has grown rapidly over the years and is today one of the leading pharmaceutical groups in Pakistan, ranked among the top 10 local pharmaceutical groups in the country with four manufacturing plants and a national presence.
OBS Group specializes in international partnerships and is known for fostering strategic alliances with reputable international companies whose products touch the lives and well-being of people around the world. The acquisition of Sandoz products is the group’s 6th acquisition since its inception in 2006. Over the years, OBS Group has acquired brands and manufacturing facilities from renowned companies such as Organon, Merck Sharp & Dohme, Schering Plow, AGP, Janssen Pharmaceuticals, and now Sandoz. The group has also entered into partnership agreements with companies such as Mylan, Santen, Vifor and Alliance Pharmaceuticals, among others.
About AGP Limited
AGP Healthcare is one of the most renowned pharmaceutical companies in Pakistan, offering a range of pharmaceuticals in gynecology, pediatrics, internal medicine, cardiology, endocrinology, gastroenterology, ophthalmology, pulmonology, hepatology and oncology.
AGP Healthcare was started as a joint venture between Eli Lilly and Ali Gohar Pharmaceuticals in Pakistan, which was subsequently acquired by OBS Group in 2014. Following the acquisition by OBS Group, the focus was on growth, l efficiency and productivity, which has resulted in significant improvements to business. Over the years, AGP Limited has partnered with many well-known companies including Eli Lilly, Alcon, Mylan, Osmopharm, Dr. Kade, UCB and Alliance Pharmaceuticals.
About the Harel group
The Harel Group is a trusted and well-known business development consultancy with an extensive global network in the biotech / pharmaceutical industry. The group connects pharmaceutical and medical device companies from around the world, facilitating win-win business transactions such as licensing, distribution, acquisitions and divestitures. The Harel Group team is made up of industry professionals with over 200 years of combined experience in the pharmaceutical industry and represents a great cultural diversity. The group is committed to delivering results quickly and efficiently while adhering to ethical business practices.
Editors Note: While The Free Press will always be free to our readers and funded by advertising, we ask our loyal readers to consider a monthly donation of $ 3 to maintain our local journalism and help us grow, as we increase sales. of advertisements locally.
You can click here to support us.
We thank you all for your consideration and for your support of local journalism.